Regentis Biomaterials Ltd. (NYSE American: RGNT) announced that the Japan Patent Office has issued a Notice of Allowance for a patent covering its proprietary organic solvent-free manufacturing process and ready-to-use liquid formulation used in GelrinC(R), the company's regenerative treatment for articular cartilage injuries. The allowance expands Regentis' global intellectual property portfolio as it advances GelrinC commercialization in Europe, continues enrollment in its pivotal U.S. clinical trial, and evaluates expansion into additional international markets.
The allowed patent covers proprietary protein-polymer conjugate compositions and manufacturing methods designed to eliminate the use of organic solvents while enabling stable liquid formulations. According to the company, the technology improves manufacturing efficiency, increases production yield, simplifies manufacturing, and enhances scalability for commercial production. This patent also strengthens Regentis' position in Japan, one of the world's largest cartilage repair markets, where demand is expected to grow as the population ages and the prevalence of knee osteoarthritis increases.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis' lead product GelrinC(R) is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is available.
The significance of this patent allowance lies in its potential to facilitate commercialization and market access in Japan, a key market for cartilage repair. The proprietary manufacturing process enhances efficiency and scalability, which could reduce costs and improve product availability. Additionally, the patent strengthens Regentis' IP portfolio, providing a competitive edge as the company progresses with its U.S. clinical trial and European commercialization. Investors can find the latest news and updates relating to RGNT in the company's newsroom at https://ibn.fm/RGNT.
The full press release is available at https://ibn.fm/w7h5A. This content has been disseminated on behalf of Regentis Biomaterials Ltd. as part of a paid investor awareness and marketing engagement.
